Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies

We present early toxicity and efficacy findings from a phase 2 trial that combines CTLA4 blockade (ipilimumab) with stereotactic ablative radiation therapy (SABR) targeting metastatic lung or liver lesions in patients with solid tumors.

http://ift.tt/2zCMrAz